Literature DB >> 17646899

IgG antibodies to plasminogen and their relationship to IgG anti-beta(2)-glycoprotein 1 antibodies and thrombosis.

Chunya Bu1, Zhihuan Li, Chune Zhang, Lei Gao, Guoping Cai.   

Abstract

Reduced fibrinolytic activity has been described in primary antiphospholipid syndrome (PAPS) and may be responsible for thrombotic events. Some evidence supports a relationship between anti-plasminogen (PLG) antibodies, anti-beta(2)-glycoprotein 1 (beta(2)GP1) antibodies, and fibrinolysis, but their relationship is still unclear. The aim of study is to evaluate the association between IgG anti-beta(2)GP1 and IgG anti-PLG antibodies and thrombosis. Two groups of consecutive patients with PAPS and systemic lupus erythematosus (SLE): 32 patients with lupus anticoagulant (LAC), 32 patients without LAC, and 40 healthy controls were included. IgG against beta(2)GP1 and PLG antibodies were measured by enzyme-linked immunosorbent assay, and a value above the 99th percentile of the normal healthy control was considered as positive, and their interrelationship with thrombosis was evaluated by Pearson Chi-squared test. Cross-reactive antibodies binding to PLG and beta(2)GP1 were determined in a competitive and cross-inhibition assay. Levels of fibrinolytic activity in the presence of IgG fractions from patients and healthy controls were examined using a plasmin fluorogenic substrate assay. A high frequency of IgG anti-PLG antibodies (35.9%) was found in 64 patients, and its presence was associated with thrombosis (p = 0.001), which may be due to its ability to inhibit exogenous fibrinolysis. Coexistence of IgG anti-PLG and IgG anti-beta(2)GP1 antibodies was found in 11 of 64 patients and was related with thrombosis (p = 0.001). Cross-reactive antibody binding to PLG and beta(2)GP1 was found in IgG fractions from three patients and a monoclonal anti-beta(2)GP1 antibody BD4, and one of these three patients had thrombotic history. However, no significant association was found between IgG anti-PLG and IgG anti-beta(2)GP1 antibodies in patients. In conclusion, the prevalence of IgG anti-PLG was high in patients with PAPS and SLE and might relate with thrombosis. Cross-reactivity of IgG anti-beta(2)GP1 antibodies with PLG may occur in the sera of patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17646899     DOI: 10.1007/s10067-007-0673-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  31 in total

1.  Purification of apolipoprotein H by polyethylene glycol precipitation.

Authors:  G Cai; Y Guo; J Shi
Journal:  Protein Expr Purif       Date:  1996-11       Impact factor: 1.650

Review 2.  Pathophysiology of the antiphospholipid syndrome.

Authors:  P G de Groot; R H W M Derksen
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

3.  Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome.

Authors:  Cai-Sheng Lu; Arash A Horizon; Kwan-Ki Hwang; John FitzGerald; Wei-Shiang Lin; Bevra H Hahn; Daniel J Wallace; Allan L Metzger; Michael H Weisman; Pojen P Chen
Journal:  Arthritis Rheum       Date:  2005-12

4.  Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.

Authors:  M Galli; P Comfurius; C Maassen; H C Hemker; M H de Baets; P J van Breda-Vriesman; T Barbui; R F Zwaal; E M Bevers
Journal:  Lancet       Date:  1990-06-30       Impact factor: 79.321

5.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

6.  Antibodies to prothrombin crossreact with plasminogen in patients developing myocardial infarction.

Authors:  M Puurunen; M Mänttäri; V Manninen; T Palosuo; O Vaarala
Journal:  Br J Haematol       Date:  1998-02       Impact factor: 6.998

7.  Characterization of IgG monoclonal anti-cardiolipin/anti-beta2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies.

Authors:  M Zhu; T Olee; D T Le; R A Roubey; B H Hahn; V L Woods; P P Chen
Journal:  Br J Haematol       Date:  1999-04       Impact factor: 6.998

Review 8.  Anti-beta2-glycoprotein I antibodies--when and how should they be measured?

Authors:  Guido Reber; Philippe de Moerloose
Journal:  Thromb Res       Date:  2004       Impact factor: 3.944

9.  Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin.

Authors:  Cheng-De Yang; Kwan-Ki Hwang; Weihong Yan; Kerry Gallagher; John FitzGerald; Jennifer M Grossman; Bevra H Hahn; Pojen P Chen
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

10.  A study on associations between antiprothrombin antibodies, antiplasminogen antibodies and thrombosis.

Authors:  M J A Simmelink; P G De Groot; R H W M Derksen
Journal:  J Thromb Haemost       Date:  2003-04       Impact factor: 5.824

View more
  2 in total

1.  Antiphospholipid Antibodies in Lupus Nephritis.

Authors:  Ioannis Parodis; Laurent Arnaud; Jakob Gerhardsson; Agneta Zickert; Birgitta Sundelin; Vivianne Malmström; Elisabet Svenungsson; Iva Gunnarsson
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

2.  Lytic Susceptibility, Structure, and Mechanical Properties of Fibrin in Systemic Lupus Erythematosus.

Authors:  Rustem I Litvinov; Rosa M Nabiullina; Laily D Zubairova; Mileusha A Shakurova; Izabella A Andrianova; John W Weisel
Journal:  Front Immunol       Date:  2019-07-16       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.